Jia Jie Biomedical Co., Ltd. (TPEX:4109)
Taiwan · Delayed Price · Currency is TWD 10.95
-0.05 (-0.45%)
Oct 8, 2026, 1:30 PM CST
Jia Jie Biomedical Ratios and Metrics
Market cap in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Oct '26 Oct 7, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 1,300 | 1,840 | 2,202 | 1,530 | 1,307 | 1,192 | |
Market Cap Growth | -31.99% | -16.41% | 43.94% | 17.01% | 9.70% | -2.60% |
Enterprise Value | 927 | 1,363 | 1,973 | 1,318 | 1,080 | 900 |
Last Close Price | 10.95 | 15.22 | 20.68 | 15.70 | 13.42 | 12.23 |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Oct '26 Oct 7, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PE Ratio | 420.36 | 36.62 | 10.42 | 10.61 | - | 223.17 |
PS Ratio | 2.53 | 3.79 | 4.10 | 4.60 | 4.12 | 4.92 |
PB Ratio | 0.79 | 1.07 | 1.62 | 1.43 | 1.42 | 1.27 |
P/TBV Ratio | 0.84 | 1.14 | 1.75 | 1.49 | 1.49 | 1.34 |
P/FCF Ratio | - | - | 89.07 | - | - | 417.57 |
P/OCF Ratio | 99.73 | 86.23 | 49.65 | - | - | 272.52 |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Oct '26 Oct 7, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
EV/Sales Ratio | 1.80 | 2.81 | 3.68 | 3.96 | 3.40 | 3.71 |
EV/EBITDA Ratio | 108.16 | 87.34 | 42.68 | - | - | 89.57 |
EV/EBIT Ratio | - | 1919.34 | 59.50 | - | - | - |
EV/FCF Ratio | - | - | 79.83 | - | - | 315.32 |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Oct '26 Oct 7, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Debt / Equity Ratio | 0.06 | 0.03 | 0.01 | 0.23 | 0.01 | 0.01 |
Debt / EBITDA Ratio | 11.25 | 3.08 | 0.17 | - | 2.76 | 0.53 |
Debt / FCF Ratio | - | - | 0.34 | - | - | 2.32 |
Net Debt / Equity Ratio | -0.24 | -0.25 | -0.19 | -0.13 | -0.26 | -0.30 |
Net Debt / EBITDA Ratio | -67.87 | -27.26 | -5.51 | 2.59 | 426.00 | -27.84 |
Net Debt / FCF Ratio | 7.72 | 6.63 | -10.30 | 10.71 | 9.20 | -98.00 |
Asset Turnover | 0.28 | 0.29 | 0.37 | 0.28 | 0.31 | 0.24 |
Inventory Turnover | 13.68 | 12.85 | 14.79 | 8.38 | 8.48 | 8.86 |
Quick Ratio | 3.61 | 3.12 | 2.68 | 1.20 | 3.71 | 3.79 |
Current Ratio | 3.87 | 3.36 | 2.98 | 1.30 | 4.32 | 4.15 |
Return on Equity (ROE) | 0.22% | 3.39% | 17.79% | 14.74% | -0.69% | 0.55% |
Return on Assets (ROA) | -0.39% | 0.03% | 1.43% | -3.42% | -0.84% | -0.06% |
Return on Invested Capital (ROIC) | -0.91% | 0.05% | 3.13% | -8.23% | -2.05% | -0.15% |
Return on Capital Employed (ROCE) | -0.70% | 0.00% | 2.40% | -6.20% | -1.50% | -0.10% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Oct '26 Oct 7, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Earnings Yield | 0.24% | 2.73% | 9.60% | 9.42% | -0.42% | 0.45% |
FCF Yield | -4.03% | -3.49% | 1.12% | -0.86% | -2.04% | 0.24% |
Dividend Yield | 1.83% | 1.31% | 2.42% | 3.19% | - | - |
Payout Ratio | 1919.43% | 118.12% | 23.36% | - | - | - |
Buyback Yield / Dilution | -11.67% | -18.72% | -10.08% | -0.29% | - | -28.10% |
Total Shareholder Return | -9.85% | -17.41% | -7.66% | 2.89% | - | -28.10% |